Repligen (RGEN)
(Delayed Data from NSDQ)
$138.82 USD
+4.33 (3.22%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $139.50 +0.68 (0.49%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$138.82 USD
+4.33 (3.22%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $139.50 +0.68 (0.49%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
Zacks News
Mirati (MRTX) Down 35.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Repligen (RGEN) Up 3.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Will Repligen's (RGEN) COVID Woes Be Offset by Product Demand?
by Zacks Equity Research
The declining pace of COVID-19 vaccination programs is likely to hurt Repligen's (RGEN) revenue growth rate in 2022. However, the strong core business is likely to offer a respite.
Repligen (RGEN) Q1 Earnings and Sales Beat Estimates, Stock Up
by Zacks Equity Research
Repligen (RGEN) reports encouraging first-quarter results with both sales and earnings beating estimates. RGEN also reduced its financial guidance for 2022
Repligen (RGEN) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 27.78% and 12.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RFG
Should Vanguard S&P MidCap 400 Growth ETF (IVOG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IVOG
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RFG
Agios (AGIO) Gets FDA Nod for Rare Anemia Drug Mitapivat
by Zacks Equity Research
Agios Pharmaceuticals' (AGIO) Pyrukynd (mitapivat) is the first disease-modifying therapy approved to treat PK deficiency, a rare, debilitating, blood disorder.
Repligen (RGEN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Repligen's (RGEN) fourth-quarter earnings and revenues beat estimates. It expects to achieve revenue growth in the range of 19-24% in 2022.
Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 24.62% and 3.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Stocks' Q4 Earnings on Feb 17: RGEN, IRWD & More
by Indrajit Bandyopadhyay
Let us take a look at four biotech or drug companies - RGEN, IRWD, EXEL and LGND - due to release their quarterly results on Feb 16.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Industry Outlook Highlights: Regeneron, Vertex Pharmaceuticals, Dynavax Technologies Corp. and Repligen
by Zacks Equity Research
Regeneron, Vertex Pharmaceuticals, Dynavax Technologies Corp. and Repligen are highlighted in this Industry Outlook article.
4 Top Biotech Stocks to Gain Amid Industry Challenges
by Ekta Bagri
New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position VRTX, REGN, DVAX and RGEN well amid the volatility.
Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RFG
Gamida (GMDA) Up on Omidubicel BLA Rolling Submission Plan
by Zacks Equity Research
The FDA agrees to the initiation of rolling submission of Gamida's (GMDA) BLA for its lead blood cancer candidate, omidubicel. The stock rises more than 22% on in response.
Should Vanguard S&P MidCap 400 Growth ETF (IVOG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IVOG
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Vertex (VRTX) Kaftrio Gets Europe Nod for CF in Children
by Zacks Equity Research
The European Commission approves Vertex's (VRTX) triple combination therapy, Kaftrio, in combination with Kalydeco for treating cystic fibrosis in children aged between six and 11 years.
Down 16.5% in 4 Weeks, Here's Why Repligen (RGEN) Looks Ripe for a Turnaround
by Zacks Equity Research
Repligen (RGEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.